David Krempa - 12 Jan 2026 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Role
Chief Business Officer
Signature
/s/ James R. Gruber
Issuer symbol
ETON
Transactions as of
12 Jan 2026
Net transactions value
-$30,334
Form type
4
Filing time
14 Jan 2026, 18:03:47 UTC
Previous filing
12 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Krempa David Chief Business Officer C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK /s/ James R. Gruber 14 Jan 2026 0001968254

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ETON Common Stock Tax liability $30,334 -1,942 -0.31% $15.62 630,238 14 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETON Employee Stock Option (Right to Buy) Award $0 +40,655 +6.5% $0.000000 670,893 12 Jan 2026 Common Stock 40,655 $15.47 Direct F3
transaction ETON Restricted Stock Units Award $0 +25,856 +3.9% $0.000000 696,749 12 Jan 2026 Common Stock 25,856 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units.
F2 The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
F3 The shares subject to the option shall vest in 48 equal monthly installments from the date of grant until fully vested and exercisable on January 12, 2030.
F4 Each restricted stock unit represents a contingent right to receive one share of ETON Common Stock.
F5 The restricted stock units vest in four equal annual installments beginning January 12, 2027, contingent upon the reporting person being employed by the issuer on the date(s) of vesting.

Remarks:

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.